New AI programming language goes beyond deep learning By: Rob Matheson | MIT News Office A team of MIT researchers is making it easier for novices to get their feet wet with artificial intelligence, while also helping experts advance the field. In a paper presented at the Programming Language Design and [..]
Adeptrix Corporation Receives Funding from ICV Venture Engineering Fund I to Accelerate Product Development Pipeline and Advance Translational Research Biology By: Jeffrey C. Silva, Ph. D. | Adeptrix Beverly, MA 01915, May 6th, 2019, Adeptrix Corporation announces the completion of initial investment through ICV Venture Engineering Fund I, for its [..]
Assessing the Place of AI in the Human Workplace By: Nick Galov For years, pop culture has painted AI as an autonomous technology that is built to help mankind but often ends up hurting it instead. As modern technology continues to steer closer towards realizing AI’s full potential, there are [..]
With new Proto Ventures Program, MIT Innovation Initiative turns ideas into impact By: Zach Winn | MIT News Office Since its launch in 2013, the MIT Innovation Initiative has been the driving force behind several projects designed to support MIT’s entrepreneurial community — but the new Proto Ventures Program may [..]
ViiV Healthcare’s Dovato, The First Regimen for Treatment-Naïve HIV-1 Adults; Approved by US FDA ViiV Healthcare today announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the treatment of HIV-1 infection in [..]
What is Quantum Computing? By: Aysha Naurein Computers have today become so common that it would be difficult for us to think of a life devoid of them. It helps us do a lot of work simultaneously, quickly, effectively and has made life a lot easier. There are better versions [..]
Writing High-Quality Publications; a textbook from 30 years of medical writing experience By: Vijay Soni, Ph.D. | Founder Scipreneur Did you know that nearly 3 million scientific papers are written each year? Yet studies suggest that most trials registered on Clinicaltrials.gov are not published in peer-reviewed journals within 2.5 years [..]
AI, the Law, and Our Future By: Peter Dizikes | MIT News Office Scientists and policymakers converged at MIT on Tuesday to discuss one of the hardest problems in artificial intelligence: How to govern it. The first MIT AI Policy Congress featured seven panel discussions sprawling across a variety of [..]
FDA Approved Firdapse® :First Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) By: Catalyst Pharmaceuticals, Inc. NEWS Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has approved Firdapse® [..]
Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease By: Novartis News Novartis announced today that the European Commission (EC) approved Luxturna, a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both [..]
FDA Grants Accelerated Approval to Genentech’s Venclexta® for Acute Myeloid Leukemia By: Genentech News Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Venclexta® (venetoclax), in combination with a hypomethylating agent (azacitidine or decitabine), or [..]
FDA Approves Novartis Drug Promacta® for First-line SAA |Breakthrough Therapy Designation By: Novartis News Basel, November 16, 2018 – Novartis announced today that the US Food and Drug Administration (FDA) has expanded the label for Promacta®(eltrombopag) to include first-line treatment for adults and pediatric patients two years and older with SAA in [..]
Viruses Against Bacteria: First TED Talk on Phage Therapy by Alexander Belcredi of PhagoMed Vienna, 16 November 2018: Today the first TED Talk on phages and phage therapy went live on TED.com. In the talk, PhagoMed’s Co-Founder and CEO Alexander Belcredi recounts how he became fascinated by phages, the history [..]
Sandoz Receives FDA Approval for Biosimilar HyrimozTM By: Novartis News Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, HyrimozTM (adalimumab-adaz). The FDA granted approval for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients [..]
Genentech Announces FDA Approval of XOFLUZA (Baloxavir Marboxil) for Influenza Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved XOFLUZA™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of [..]
National Fellowships for Graduates/Post Graduates Students, India :2 By: Dr. Richa Lakhotia Here is the remaining list of all other fellowships. 14. Postdoctoral Fellowships in Physics at Harish-Chandra Research Institute in India, 2018 The Harish-Chandra Research Institute is delighted to offer its postdoctoral fellowships in Physics for Indian students. The fellowships [..]
Alcon to Develop SMART Suite digital health platform for cataract surgery By: Novartis News| Alcon Alcon, the global leader in eye care and a division of Novartis, today announced plans to develop the SMART Suite by Alcon, an innovative, digital platform that is designed to streamline, simplify and improve [..]
National Fellowships for Graduates/Post Graduates Students, India | TOC 1 By: Dr. Richa Lakhotia There are many exciting programs and funding opportunities to support graduates/post graduates students in India. Check out these fellowships available for indian students with varying academic backgrounds. (1) Extra Mural Research Funding (Individual Centric) Individual centric competitive mode of [..]
Libtayo® Received FDA Aproval As First And Only Treatment For Second Most Common Skin Cancer Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Libtayo® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery [..]
FDA Approved the First and Only Therapy for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of ARIKAYCE® (amikacin liposome inhalation suspension) for the [..]
FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies By: Genentech News Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Xolair® (omalizumab) for the prevention of severe allergic reactions [..]
FDA Approved First siRNA Based New Class of Drug for a Rare Genetic Disease By: Alnylam News Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) approved ONPATTRO™ (patisiran) lipid complex injection, a first-of-its-kind RNA interference (RNAi) therapeutic, for the treatment [..]
New Era for Migraine Patients: EU Approved Aimovig® of Novartis Novartis announced that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be approved [..]
EPIDIOLEX®:First FDA-approved Drug Derived From Marijuana GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that the U.S. Food and Drug Administration [..]
FDA Approves TPOXX® :The First Drug For Smallpox SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) has approved oral TPOXX® (tecovirimat) for the treatment of smallpox to mitigate the impact of a potential outbreak. TPOXX, a small-molecule [..]
World’s first Gesture based workflow automation device, The KAI launches on Indegogo this May Bangalore, India, May 22, 2018 KAI launches on the crowd funding site Indegogo. Starting from $129 for early bird special. The KAI is a gesture based wearable controller that enhances intuitive digital interaction. The Kai harnesses [..]
Novartis’s Gilenya® got Approved by FDA for Pediatric Relapsing Multiple Sclerosis By: Novartis News Novartis announced that the US Food and Drug Administration (FDA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with relapsing forms of multiple sclerosis (RMS), making [..]
FDA Grants Priority Review to Genentech’s Cancer Immunotherapy Tecentriq By: Genentech News Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination [..]
Tafinlar® + Mekinist® of Novartis Receives FDA Approval for the Treatment of BRAF V600-Mutant Melanoma By: Novartis News Novartis announced that the US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as [..]
Novartis Receives Second FDA Approval for Kymriah® to Treat B-cell Lymphoma By: Novartis News Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication – the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two [..]
Copyright © 2024 | WordPress Theme by MH Themes